Flonase
Symbol:
Class Period:
Status:
Active
Documents:
Case Update
Motion to dismiss denied.
Case Summary
This case alleges Defendant GlaxoSmithKline filed baseless citizens petitions with the Food and Drug Administration in order to prevent or delay generic entry by Roxanne Laboraties, Inc. The Complaint alleges that the filing of these baseless petitions caused at least a twenty month delay, thereby forcing consumers and health insurers to purchase the more expensive branded Flonase product. The firm serves as Co-Lead Counsel in this case which is pending in the United States District Court, Eastern District of Pennsylvania.
